Reactogenicity, immunogenicity, and efficacy of a chick embryo cell-derived vaccine for Rocky Mountain spotted fever

M. L. Clements, C. L. Wisseman, T. E. Woodward, P. Fiset, J. S. Dumler, W. McNamee, R. E. Black, J. Rooney, T. P. Hughes, M. M. Levine

Research output: Contribution to journalArticlepeer-review

Abstract

A new formalin-inactivated vaccine prepared by sucrose density gradient centrifugation of tissue-grown Rickettsia rickettsii was evaluated for safety and immunogenicityicity in a placebo-controlled, double-blind study. Most of the 52 seronegative adult vaccinees, 88% after the first and 66% after the second dose, experienced brief, mild (mostly local) reactions, but only 50% exhibited a systemic immune response to vaccination. Six unvaccinated volunteers (controls) and 16 of these vaccinees were challenged with R rickettsii one monthe after vaccination. Vaccine efficacy was 25%; all six controls and 12 of 16 vaccinees developed typical Rocky Mountain spotted fever. The incubation period was longer, the duration of constitutional symptoms shorter, and the height of fever lower in ill vaccinees than in controls. The vaccine provided only partial protection against Rocky mountain spotted fever but ameliorated the illness.

Original languageEnglish (US)
Pages (from-to)922-930
Number of pages9
JournalJournal of Infectious Diseases
Volume148
Issue number5
DOIs
StatePublished - 1983

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Reactogenicity, immunogenicity, and efficacy of a chick embryo cell-derived vaccine for Rocky Mountain spotted fever'. Together they form a unique fingerprint.

Cite this